Form 4: Adiumentum Capital Fund I LP Reports Changes in Beneficial Ownership of Atara Biotherapeutics, Inc.

Adiumentum Capital Fund I LP, along with related entities and Gregory A. Ciongoli, filed a Form 4 detailing changes in their beneficial ownership of Atara Biotherapeutics, Inc. securities, including the acquisition of common stock and warrants.

Summary

• Adiumentum Capital Fund I LP, Adiumentum Capital Fund I GP LLC, and Gregory A. Ciongoli (the 'Reporting Persons') jointly filed a Form 4 with the SEC.
• The filing reports changes in beneficial ownership of Atara Biotherapeutics, Inc. (ATRA) securities.
• On May 16, 2025, Adiumentum acquired 75,572 shares of common stock at a price of $6.61 per share.
• Adiumentum also disposed of 1,209,395 shares of common stock.
• Additionally, Adiumentum acquired 227,000 warrants with an exercise price of $0.0001.
• The warrants are immediately exercisable and do not expire.
• The Reporting Persons disclaim beneficial ownership of the Subject Securities, except to the extent of any pecuniary interest therein.
• Mr. Ciongoli serves as a director on the Board of Directors of the Issuer and, as a result, the entities listed in these notes are directors by deputization.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing changes in ownership. It doesn't inherently convey positive or negative sentiment.

Risks

• The Issuer may not effect any exercise of any warrant, and a holder of a warrant does not have the right to exercise any portion of the warrant held by such holder, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of common stock would be aggregated with such holder's for the purposes of Section 13(d) of the Exchange Act, and the applicable regulations of the U.S. Securities and Exchange Commission, including any 'group' of which such holder is a member, would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders and major shareholders.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure and transactions of major stakeholders.
• The transactions may influence investor perception of the company's stock.

Key Dates

Keywords

beneficial ownership, Form 4, Adiumentum Capital Fund I LP, Atara Biotherapeutics, Gregory A. Ciongoli, warrants, common stock, securities